Table 4.
Determinants of time to achieve HAQ-DI ≤ 0.5 mm and achievement at week 100 among guselkumab-randomized patients (N = 493)
| Independent baseline variables | Time to HAQ-DI ≤ 0.5 achievement | Achievement of HAQ-DI ≤ 0.5 at W100 | ||
|---|---|---|---|---|
| HR (95% CI) | OR (95% CI) | |||
| All covariates | Backward selection | All covariates | Backward selection | |
| Age, years | 0.98 (0.97–0.99)† | 0.98 (0.97–0.99) † | 0.98 (0.96–1.00)* | 0.98 (0.96–1.00) * |
| Sex (male vs. female) | 1.17 (0.90–1.52) | - | 1.38 (0.90–2.13) | - |
| Race (White vs. Asian) | 2.36 (0.58–9.66) | - | 2.52 (0.50–12.69) | - |
| BMI, kg/m2 | 0.99 (0.97–1.02) | - | 0.98 (0.95–1.02) | - |
| Guselkumab treatment (Q4W vs., Q8W) | 1.01 (0.79–1.30) | - | 0.98 (0.64–1.51) | - |
| HAQ-DI score (0-3) | 0.32 (0.23–0.45)‡ | 0.26 (0.19–0.36) ‡ | 0.16 (0.10–0.27)‡ | 0.13 (0.08–0.20) ‡ |
| PtGA VAS (0–10 cm) | - | - | - | - |
| Pt Pain VAS (0–10 cm) | - | - | - | - |
| FACIT-Fatigue§ | 1.01 (1.00–1.03) | - | 1.02 (0.99–1.05) | - |
| History of depression | 1.55 (0.64–3.77) | - | 1.98 (0.35–11.30) | - |
| Suicidal ideation or non-suicidal self-injurious behaviour (N = 9) | 0.20 (0.03–1.42) | - | 0.15 (0.03–0.88)* | 0.16 (0.03–0.86) * |
| History of fibromyalgia (N = 3) | 0.87 (0.68–1.13) | - | 0.84 (0.54–1.30) | - |
BMI = body mass index; CI = confidence interval; FACIT = Functional Assessment of Chronic Illness Therapy; HAQ-DI = Health Assessment Questionnaire-Disability Index; HR = hazard ratio; OR = odds ratio; Pt = patient; PtGA = patient global assessment; Q4W = every 4 weeks; Q8W = every 8 weeks; VAS = visual analog scale; W = week
*p < 0.05; †p < 0.01; ‡p ≤ 0.0001
§Higher score indicates less fatigue